NLRP3 and diabetic retinopathy: Studies identified that inhibiting NLRP3 inflammasome activation could ameliorate diabetic cardiomyopathy [34], diabetic retinopathy [35], diabetic nephropathy [36], and diabetic vascular endothelial dysfunction [21].